Moberg Pharma AB (OSTO:MOB) Total Equity: kr662.92 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MOB Moberg Pharma AB OSTO:MOB
37 GF Score
Price kr11.14
! 2 Warning Signs
View Full Analysis

What is Moberg Pharma AB Total Equity?

Moberg Pharma AB OSTO:MOB -2.28% 37 Total Equity is kr662.92 Mil as of Jun. 2026. GuruFocus rates OSTO:MOB with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Moberg Pharma AB's total equity for the quarter that ended in Jun. 2026 was kr662.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Moberg Pharma AB Total Equity Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Total Equity Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 434.05 533.58 610.73 686.82 665.22

Moberg Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 679.71 676.90 665.22 665.14 662.92
OSTO:MOB
37GF Score
Moberg Pharma AB OSTO:MOB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Moberg Pharma AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=682.264-17.044
=665.22

Moberg Pharma AB's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=681.393-18.475
=662.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr662.92 Mil mean?
Moberg Pharma AB (OSTO:MOB) has a Total Equity of kr662.92 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Total Equity too high?
Moberg Pharma AB's current Total Equity is kr662.92 Mil. Overall, Moberg Pharma AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Total Equity compare to ZTS?
Moberg Pharma AB's Total Equity of kr662.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors. Moberg Pharma AB's current Total Equity is kr662.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (OSTO:MOB) has a current Total Equity of kr662.92 Mil. The current Total Equity is kr662.92 Mil. Moberg Pharma AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Moberg Pharma AB (OSTO:MOB), the current Total Equity is kr662.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USA
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
37GF Score

Get the complete analysis for OSTO:MOB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.14
Price